Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case

Birgit Knoechel, Ami S. Bhatt, Pan Li, Chandra Sekhar Pedamallu, Eric A. Severson, Alejandro Gutiérrez, David M. Dorfman, Frank C. Kuo, Michael Kluk, Andrew L. Kung, Patrick A. Zweidler‐McKay, Matthew Meyerson, Stephen C. Blacklow, Daniel J. DeAngelo, Jon C. AsterMolecular 2015 · DOI

Abstract

Notch pathway antagonists such as γ-secretase inhibitors (GSIs) are being tested in diverse cancers, but exceptional responses have yet to be reported. We describe the case of a patient with relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) who achieved a complete hematologic response following treatment with the GSI BMS-906024. Whole-exome sequencing of leukemic blasts revealed heterozygous gain-of-function driver mutations in NOTCH1, CSF3R, and PTPN11, and a homozygous/hemizygous loss-of-function mutation in DNMT3A. The three gain-of-function mutations were absent from remission marrow cells, but the DNMT3A mutation persisted in heterozygous form in remission marrow, consistent with an origin for the patient's ETP-ALL from clonal hematopoiesis. Ex vivo culture of ETP-ALL blasts confirmed high levels of activated NOTCH1 that were repressed by GSI treatment, and RNA-seq documented that GSIs downregulated multiple known Notch target genes. Surprisingly, one potential target gene that was unaffected by GSIs was MYC, a key Notch target in GSI-sensitive T-ALL of cortical T-cell type. H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. To our knowledge, this is the first example of complete response of a Notch-mutated ETP-ALL to a Notch antagonist and is also the first description of chromatin landscapes associated with ETP-ALL. Our experience suggests that additional attempts to target Notch in Notch-mutated ETP-ALL are merited.

Introduction

Early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) is an aggressive subtype of T-ALL associated with a poor prognosis and resistance to standard therapies. Historically, ETP-ALL was thought to lack the NOTCH1 mutations common in other T-ALL subtypes, leading to the exclusion of these patients from clinical trials for Notch pathway inhibitors like γ-secretase inhibitors (GSIs). This paper details an "outlier case"—a 53-year-old man with relapsed/refractory ETP-ALL who achieved a remarkable complete hematologic response to the GSI BMS-906024.

Methods

Researchers utilized a multi-omic approach to analyze the patient's response. Genomic analysis included Targeted Exome Sequencing (TES) and Whole-Exome Sequencing (WES) on leukemic blasts, remission marrow, and saliva. Transcriptomic changes were tracked via RNA-seq to identify genes regulated by GSI treatment. Additionally, H3K27ac ChIP-seq was employed to map super-enhancers and define the epigenetic landscape of the ETP-ALL blasts. Functional sensitivity to GSIs and BRD4 inhibitors (JQ1) was validated through ex vivo primary cell cultures.

Results

Genomic sequencing identified a novel NOTCH1 mutation (F1592C) in the negative regulatory region (NRR) that drives ligand-independent pathway activation. Other driver mutations included CSF3R and PTPN11. A DNMT3A mutation was found to persist in remission marrow, suggesting the leukemia arose from a state of clonal hematopoiesis.

Clinical response was rapid; peripheral blasts dropped from 85% to 0% within weeks. By 7 weeks, the patient achieved a complete hematologic response (CHR) and was negative for minimal residual disease (MRD < $1 \times 10^{-6}$).

Bone marrow biopsy at 7 weeks showing complete hematologic response.

Transcriptomic and epigenetic analysis revealed a "MYC surprise." Unlike typical T-ALL where Notch directly drives MYC expression, MYC in this patient was unaffected by GSI. ChIP-seq showed that MYC was controlled by a super-enhancer landscape characteristic of acute myeloid leukemia (AML). Consequently, while MYC was insensitive to Notch inhibition, the blasts were sensitive to the BRD4 inhibitor JQ1.

Discussion

This case represents the first documented complete response of a Notch-mutated ETP-ALL to a Notch antagonist. The findings suggest that even when MYC regulation follows an AML-like pattern, other Notch targets (such as HES1) remain critical for leukemic survival. These results argue for the inclusion of ETP-ALL patients in future Notch inhibitor trials and suggest that combining GSIs with BRD4 inhibitors could provide a potent therapeutic strategy for this high-risk leukemia subtype.

Summary updated

Abstract

Notch pathway antagonists such as γ-secretase inhibitors (GSIs) are being tested in diverse cancers, but exceptional responses have yet to be reported. We describe the case of a patient with relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) who achieved a complete hematologic response following treatment with the GSI BMS-906024. Whole-exome sequencing of leukemic blasts revealed heterozygous gain-of-function driver mutations in NOTCH1, CSF3R, and PTPN11, and a homozygous/hemizygous loss-of-function mutation in DNMT3A. The three gain-of-function mutations were absent from remission marrow cells, but the DNMT3A mutation persisted in heterozygous form in remission marrow, consistent with an origin for the patient's ETP-ALL from clonal hematopoiesis. Ex vivo culture of ETP-ALL blasts confirmed high levels of activated NOTCH1 that were repressed by GSI treatment, and RNA-seq documented that GSIs downregulated multiple known Notch target genes. Surprisingly, one potential target gene that was unaffected by GSIs was MYC, a key Notch target in GSI-sensitive T-ALL of cortical T-cell type. H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. To our knowledge, this is the first example of complete response of a Notch-mutated ETP-ALL to a Notch antagonist and is also the first description of chromatin landscapes associated with ETP-ALL. Our experience suggests that additional attempts to target Notch in Notch-mutated ETP-ALL are merited.
BibTeX
@inproceedings{knoechel2015complete,
  author = {Birgit Knoechel and Ami S. Bhatt and Pan Li and Chandra Sekhar Pedamallu and Eric A. Severson and Alejandro Gutiérrez and David M. Dorfman and Frank C. Kuo and Michael Kluk and Andrew L. Kung and Patrick A. Zweidler‐McKay and Matthew Meyerson and Stephen C. Blacklow and Daniel J. DeAngelo and Jon C. Aster},
  title = {{Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.1101/mcs.a000539},
}
Figure